Meridian Clinical Research Ranked on the 2020 Inc. 5000 List

Inc. magazine ranked Meridian Clinical Research as 2,938 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Omaha, NE, Meridian is a multi-specialty site network with 24 sites nationwide. “It’s an honor to be recognized,” said Nicole Osborn, Meridian founder and CEO. “Our goal has always been to grow sustainably by partnering with leading physicians to drive high quality research.” The company’s ranking reflects growth from 2016 to 2019, but Osborn said 2020 has been Meridian’s most remarkable year … Read more

Meridian Clinical Research Begins Recruiting Healthy Adults for COVID-19 Vaccine Clinical Trial

Meridian Clinical Research announced today it has begun recruiting healthy adults for a Phase 3 clinical research study to evaluate the safety and effectiveness of mRNA-1273, a vaccine candidate against COVID-19. Sponsored by Moderna, the COVE Study is recruiting healthy volunteers ages 18 or older in high-risk populations, including the elderly, racial and ethnic minorities at higher risk for COVID-19, and essential workers in close contact with potentially infected persons. The Phase 3 study will evaluate if mRNA-1273 boosts the immune system to produce enough antibodies against SARS-CoV-2, … Read more

Operation Warp Speed Leaders Visit Meridian Clinical Research Site in Savannah, Discuss COVID-19 Vaccine Research Progress

Leaders of the Operation Warp Speed (OWS) program visited Meridian Clinical Research’s internal medicine site in Savannah, GA. Visitors included Moncef Slaoui, chief advisor, and General Gustave F. Perna, chief operating officer, of OWS. In May, the federal government announced the OWS program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. Paul Bradley, MD, principal investigator at Meridian, enrolled the first patient into a Phase III COVID-19 vaccine clinical trial at the Savannah site on Monday, July 27, 2020. Meridian is conducting Phase … Read more

Paul Bradley, MD, Enrolls First Participant in Moderna’s Phase III COVID-19 Vaccine Clinical Trial

The first participant in the Moderna Phase III COVID-19 vaccine trial was enrolled this morning by Dr. Paul Bradley, Principal Investigator at Meridian’s internal medicine site in Savannah, GA. Compliments to Moderna on this significant milestone for its mRNA vaccine candidate (mRNA-1273) against COVID-19. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid

Meridian Clinical Research Opens Sites in Grand Island and Hastings, NE, Now Enrolling for COVID-19 Vaccine Studies

Meridian Clinical Research, a leading multi-specialty investigative research network, has opened new sites in Grand Island, NE, and Hastings, NE. Meridian is partnering with Adam Brosz, MD, Erica Haake, MD, and Timothy Gardner, MD, in Grand Island. The physicians will serve as principal investigators to conduct clinical trials related to general medicine, women’s health, pediatrics, and infectious diseases. The site will operate within the Grand Island Clinic at 2444 West Faidley Avenue, Grand Island, Nebraska 68803. In Hastings, Meridian is partnering with Tyler Adam, MD, and Daniel Leonard, … Read more

Keith Vrbicky, MD, Enrolls First Participant in Moderna’s Phase II COVID-19 Vaccine Clinical Trial

The first participant in the Moderna Phase II COVID-19 vaccine trial was enrolled morning by Keith Vrbicky, MD, Meridian Principal Investigator in Norfolk, NE. Congratulations to Moderna for making remarkable progress on its mRNA vaccine against novel coronavirus. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase

Meridian Clinical Research is Seeking Participants for COVID-19 Vaccine Studies in GA, NE, and SD

Meridian Clinical Research, a leading investigative research network, is seeking participants for COVID-19 vaccine clinical trials in the following areas: Nebraska (Norfolk and Omaha), Georgia (Savannah), and South Dakota (Dakota Dunes). The studies will help determine the safety and efficacy of investigational vaccines intended to protect against SARS-CoV-2 (the coronavirus that causes COVID-19). To be eligible, participants must: Be adults, age 18 or older (19 or older in Nebraska) Not have a history of SARS-CoV-2 infection Not be pregnant or breastfeeding Eligible participants will receive compensation for participating … Read more

Article by Andrew Kimball: Business Development for Research Sites

Andrew Kimball, vice president, business development (BD), recently published an article in SCRS InSite that highlights the importance of BD at research sites and networks. The article outlines BD’s role in enhancing feasibility processes, opportunity sourcing, and the nurturing of long-term partnerships with Sponsors and CROs. ? Full article: https://cloud.3dissue.com/180561/181052/211361/SpringInsite2020/index.html?page=6

Meridian Continues to Support Trials at Sites Nationwide, Will Remain Operational Amid COVID-19 Pandemic

Meridian Clinical Research, a leading investigative research network, will remain open to support the research of investigational tests, vaccines, and medications intended for commercial release. Meridian sites are working with Sponsors and contract research organizations (CROs) to ensure patient safety while continuing to enroll patients during the COVID-19 pandemic. The company has enrolled more than 25,000 subjects into vaccine and infectious disease clinical trials in the past 20 years. Nicole Osborn, CEO, says Meridian has always focused on protecting healthy participants and patients with acute conditions. “We’re fully … Read more